GS‐0189 was designed as an alternative to magrolimab, an anti‐CD47 monoclonal antibody (mAb) in clinical development in hematologic malignancies and solid tumors, as it had been found not to impact red blood cells in preclinical experiments [23]. The gene discussed is CD47; the disease is hematologic disorder.